CalciMedica
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
505 Coast Blvd S Ste 307, La Jolla, Cali...Phone Number
(858) 952-5500Website
www.calcimedica.comRevenue
<$5 MillionStock Symbol
CALCIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About CalciMedica
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.Explore more
CalciMedica Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CalciMedica your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when CalciMedica launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on CalciMedica recently announced quarterly report
Click to see if CalciMedica had a recent Job posting/layoffs
Funding: Get notified immidiatlly once CalciMedica has new funding data
Check if CalciMedica has recently received funding, and reach out quickly before it becomes old news!
Check out if CalciMedica is spiking on competitors!
CalciMedica, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at CalciMedica
Recommended Actions
Reach out to Masked Content who joined CalciMedica as Masked Content
Find 2 more new buyers
Compare Similar Companies to CalciMedica
Compare insights from companies similar to CalciMedica, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CalciMedica is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CalciMedica is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CalciMedica.
CalciMedica financials insights
Gather financial insights about CalciMedica, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Debt
$9.2M
2011
Unspecified
$6M
Debt
$4M
2012
Debt
$13.2M
Debt
$4.6M
2013
Debt
$3M
2014
Private Equity
$2.5M
2020
Series C
$15M
2021
Series D
$21M
CalciMedica Tech Stack
A closer look at the technologies used by CalciMedica
Most Recent Scoops
Earnings
Earnings, Finance
Project
Laboratory Operations, Medical Research, Clinical Operations
Earnings
Earnings, Finance
Person-Based
Earnings
Earnings, Finance
CalciMedica News & Media
CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program
Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway...CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data
FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026...CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates
FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension...CalciMedica (CALC) CMO awarded 91173 options at $0.585 exercise price - Stock Titan
CalciMedica’s Chief Medical Officer received 91,173 employee stock options at a $0.585 exercise price, vesting monthly over four years starting April 1, 2026, subject to a Form S-8 condition.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CalciMedica
Sign Up For FreeTo access detailed company insights
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in... Read More
